DHX32

Summary

DHX32 (DEAH-box helicase 32 (putative), HGNC:16717) is a protein-coding gene on chromosome 10q26.2, encoding Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX32 (Q7L7V1).

DEAD box proteins, characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD), are putative RNA helicases. They are implicated in a number of cellular processes involving alteration of RNA secondary structure such as translation initiation, nuclear and mitochondrial splicing, and ribosome and spliceosome assembly. Based on their distribution patterns, some members of this DEAD box protein family are believed to be involved in embryogenesis, spermatogenesis, and cellular growth and division. This gene encodes a member of this family. The function of this member has not been determined. Alternative splicing of this gene generates 2 transcript variants, but the full length nature of one of the variants has not been defined.

Source: NCBI Gene 55760 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Moderate, GenCC) — +2 more curated relationships
• GWAS associations: 3
• Clinical variants (ClinVar): 257 total
• Druggable target: yes
• MANE Select transcript: NM_018180

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16717
Approved symbol	DHX32
Name	DEAH-box helicase 32 (putative)
Location	10q26.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10889, FLJ10694, DHLP1
Ensembl gene	ENSG00000089876
Ensembl biotype	protein_coding
OMIM	607960
Entrez	55760

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 8 protein_coding

ENST00000284690, ENST00000368721, ENST00000415732, ENST00000900795, ENST00000900796, ENST00000963219, ENST00000963220, ENST00000963221

RefSeq mRNA: 1 — MANE Select: NM_018180 NM_018180

CCDS: CCDS7652

Canonical transcript exons

ENST00000284690 — 11 exons

Exon	Start	End
ENSE00001016202	125853961	125854203
ENSE00001432213	125836337	125836855
ENSE00001605803	125866990	125867183
ENSE00001616174	125859603	125859975
ENSE00001616476	125841743	125841934
ENSE00001703710	125838206	125838387
ENSE00001711821	125880543	125881292
ENSE00001713789	125840847	125840996
ENSE00001737019	125852293	125852451
ENSE00001784227	125839001	125839188
ENSE00003567692	125852543	125852642

Expression profiles

Bgee: expression breadth ubiquitous, 289 present calls, max score 96.37.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 7.3276 / max 54.2742, expressed in 1737 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
111909	7.0897	1734
111908	0.1038	27
111907	0.0824	50
111906	0.0516	23

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
nasal cavity epithelium	UBERON:0005384	96.37	gold quality
esophagus squamous epithelium	UBERON:0006920	96.13	gold quality
tongue squamous epithelium	UBERON:0006919	95.60	gold quality
squamous epithelium	UBERON:0006914	95.41	gold quality
parotid gland	UBERON:0001831	95.32	gold quality
gingival epithelium	UBERON:0001949	95.28	gold quality
epithelium of esophagus	UBERON:0001976	94.77	gold quality
adrenal tissue	UBERON:0018303	94.74	gold quality
gingiva	UBERON:0001828	94.73	gold quality
cardia of stomach	UBERON:0001162	94.64	gold quality
amniotic fluid	UBERON:0000173	94.58	gold quality
lateral globus pallidus	UBERON:0002476	94.33	gold quality
mucosa of sigmoid colon	UBERON:0004993	94.24	gold quality
colonic mucosa	UBERON:0000317	94.06	gold quality
type B pancreatic cell	CL:0000169	94.01	silver quality
nasal cavity mucosa	UBERON:0001826	93.99	gold quality
lateral nuclear group of thalamus	UBERON:0002736	93.98	gold quality
left ventricle myocardium	UBERON:0006566	93.93	gold quality
olfactory bulb	UBERON:0002264	93.85	silver quality
olfactory segment of nasal mucosa	UBERON:0005386	93.59	gold quality
myocardium	UBERON:0002349	93.48	gold quality
pharyngeal mucosa	UBERON:0000355	93.35	gold quality
rectum	UBERON:0001052	93.30	gold quality
body of tongue	UBERON:0011876	93.19	gold quality
male germ cell	CL:0000015	93.03	gold quality
upper arm skin	UBERON:0004263	92.91	gold quality
pancreatic ductal cell	CL:0002079	92.88	gold quality
secondary oocyte	CL:0000655	92.77	gold quality
sperm	CL:0000019	92.72	gold quality
heart right ventricle	UBERON:0002080	92.61	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.72

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

48 targeting DHX32, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-548AC	99.84	70.77	4351
HSA-MIR-548H-3P	99.84	70.80	4349
HSA-MIR-548Z	99.84	70.80	4349
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-2116-3P	99.74	64.32	889
HSA-MIR-3059-5P	99.70	69.93	2491
HSA-MIR-1283	99.69	72.42	3009
HSA-MIR-4530	99.69	66.47	1509
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-133A-3P	99.27	71.53	1270
HSA-MIR-133B	99.27	71.53	1270
HSA-MIR-642A-3P	99.23	67.67	1258
HSA-MIR-642B-3P	99.23	67.67	1258

Literature-anchored findings (GeneRIF, showing 9)

• Structural characterization and expression of the DDX32 gene. Expression studies show that DDX32 is widespread but specifically down-regulated in acute lymphoblastic leukemias and might play a role in normal and/or abnormal lymphopoiesis. (PMID:12163057)
• cloned DHX32 proximal promoter and identified a 218bp fragment containing two potential binding sites for the transcription factor nuclear factor of activated T cells (NF-AT) (PMID:16414036)
• These results suggest that DHX32 is a putative RNA helicase that might be involved in regulating nuclear and mitochondrial gene expression. (PMID:16959245)
• dysregulated expression of DHX32 might lead to as of yet unknown changes in mitochondrial homeostasis manifested by cytoplasmic redistribution of the molecular chaperon Hsp60 (PMID:17174952)
• In peripheral blood lymphocytes, a correlation between DHX32 and c-FLIP short expression was detected in response to different T-cell activation stimuli. Results suggest DHX32 involvement in regulating T-cell response to apoptotic stimuli. (PMID:17352256)
• DHX32 may play an important role in the development of colorectal cancer and could serve as a novel biomarker for colorectal cancer after additional investigation. (PMID:19161603)
• DHX32 is an upstream regulator for beta-catenin, which promotes the activity of beta-catenin to upregulate expression of VEGFA in colorectal cancer cells. Depletion of DHX32 expression suppressed colorectal cancer tumor angiogenesis and tumor growth. (PMID:28330603)
• Hypoxia-induced changes in intragenic DNA methylation correlate with alternative splicing in breast cancer. (PMID:31965981)
• DEAH-box polypeptide 32 promotes hepatocellular carcinoma progression via activating the beta-catenin pathway. (PMID:33729094)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	dhx32a	ENSDARG00000077461
danio_rerio	dhx32b	ENSDARG00000079029
mus_musculus	Dhx32	ENSMUSG00000030986
rattus_norvegicus	Dhx32	ENSRNOG00000018119

Paralogs (18): DHX33 (ENSG00000005100), YTHDC2 (ENSG00000047188), DHX29 (ENSG00000067248), DHX8 (ENSG00000067596), DHX35 (ENSG00000101452), DHX40 (ENSG00000108406), DHX15 (ENSG00000109606), HELB (ENSG00000127311), DHX30 (ENSG00000132153), DHX34 (ENSG00000134815), DHX9 (ENSG00000135829), DHX38 (ENSG00000140829), DQX1 (ENSG00000144045), DHX37 (ENSG00000150990), TDRD9 (ENSG00000156414), DHX57 (ENSG00000163214), DHX36 (ENSG00000174953), DHX16 (ENSG00000204560)

Protein

Protein identifiers

Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX32 — Q7L7V1 (reviewed: Q7L7V1)

Alternative names: DEAD/H box 32, DEAD/H helicase-like protein 1, DEAH box protein 32, HuDDX32

All UniProt accessions (3): Q7L7V1, X6R717, X6RHK1

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Nucleus. Mitochondrion.

Tissue specificity. Expressed in lymphoid tissues (at protein level). Expressed in brain, heart, skeletal muscle, colon, thymus, spleen, kidney, liver, small intestine, placenta, lung, lymphoid tissues and blood leukocytes.

Induction. Up-regulated by ionomycin in T-lymphocytes. Down-regulated in acute lymphoblastic leukemia.

Similarity. Belongs to the DEAD box helicase family. DEAH subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q7L7V1-1	1	yes
Q7L7V1-2	2

RefSeq proteins (1): NP_060650* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007502	Helicase-assoc_dom	Domain
IPR011709	DEAD-box_helicase_OB_fold	Domain
IPR014001	Helicase_ATP-bd	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR048333	HA2_WH	Domain

Pfam: PF04408, PF07717, PF21010

Catalyzed reactions (Rhea), 1 shown:

• ATP + H2O = ADP + phosphate + H(+) (RHEA:13065)

UniProt features (21 total): sequence conflict 10, sequence variant 4, chain 1, domain 1, region of interest 1, short sequence motif 1, binding site 1, modified residue 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7L7V1-F1	86.34	0.69

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 85–92

Post-translational modifications (1): 1

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 121 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_DN, TTTGTAG_MIR520D, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, RAMPON_ENRICHED_LEARNING_ENVIRONMENT_LATE_UP, GOCC_SPLICEOSOMAL_COMPLEX, GOCC_RIBONUCLEOPROTEIN_COMPLEX, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_ACID_ANHYDRIDES, ROVERSI_GLIOMA_COPY_NUMBER_DN, COULOUARN_TEMPORAL_TGFB1_SIGNATURE_UP, DODD_NASOPHARYNGEAL_CARCINOMA_DN, GOMF_ATP_HYDROLYSIS_ACTIVITY, GOMF_ADENYL_NUCLEOTIDE_BINDING, GOMF_ISOMERASE_ACTIVITY, TEF_Q6

GO Biological Process (0):

GO Molecular Function (8): RNA binding (GO:0003723), RNA helicase activity (GO:0003724), helicase activity (GO:0004386), ATP binding (GO:0005524), ATP hydrolysis activity (GO:0016887), nucleotide binding (GO:0000166), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (3): spliceosomal complex (GO:0005681), mitochondrion (GO:0005739), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
ATP-dependent activity	2
intracellular membrane-bounded organelle	2
nucleic acid binding	1
helicase activity	1
ATP-dependent activity, acting on RNA	1
catalytic activity, acting on RNA	1
nucleic acid conformation isomerase activity	1
catalytic activity, acting on a nucleic acid	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
ribonucleoside triphosphate phosphatase activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
catalytic activity	1
nuclear protein-containing complex	1
ribonucleoprotein complex	1
cytoplasm	1

Protein interactions and networks

STRING

2428 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DHX32	BCCIP	Q9P287	960
DHX32	UROS	P10746	886
DHX32	FANK1	Q8TC84	673
DHX32	FAM199X	Q6PEV8	580
DHX32	BYSL	Q13895	575
DHX32	ABT1	Q9ULW3	542
DHX32	DDX49	Q9Y6V7	527
DHX32	GRIFIN	A4D1Z8	512
DHX32	DDX10	Q13206	501
DHX32	MEAK7	Q6P9B6	488
DHX32	DDX55	Q8NHQ9	485
DHX32	BRIX1	Q8TDN6	483
DHX32	ZBTB8B	Q8NAP8	470
DHX32	ZNF717	Q9BY31	460
DHX32	ZNF595	Q8IYB9	448

IntAct

48 interactions, top by confidence:

A	B	Type	Score
FAM161A	DHX32	psi-mi:“MI:0915”(physical association)	0.840
DHX32	FAM161A	psi-mi:“MI:0915”(physical association)	0.840
DHX32	POLRMT	psi-mi:“MI:0914”(association)	0.530
LIPH	LRP5	psi-mi:“MI:0914”(association)	0.530
FBXL17	KLHL2	psi-mi:“MI:0914”(association)	0.530
LRRC27	HMOX1	psi-mi:“MI:0914”(association)	0.530
MRPL16	MRPL2	psi-mi:“MI:0914”(association)	0.530
Mecom	ESYT2	psi-mi:“MI:0914”(association)	0.350
BCL2L14		psi-mi:“MI:0914”(association)	0.350
NT5C3A	VWA8	psi-mi:“MI:0914”(association)	0.350
VMP1	TPM3	psi-mi:“MI:0914”(association)	0.350
ZNF785	CASK	psi-mi:“MI:0914”(association)	0.350
ZBBX	ZZEF1	psi-mi:“MI:0914”(association)	0.350
rep	B4GALT3	psi-mi:“MI:0914”(association)	0.350
LIPH	B4GALT5	psi-mi:“MI:0914”(association)	0.350
NOBOX	CDK2	psi-mi:“MI:0914”(association)	0.350
ZNF136	STAT4	psi-mi:“MI:0914”(association)	0.350
FAM153A	ANKRD13D	psi-mi:“MI:0914”(association)	0.350
SSX7	DHX32	psi-mi:“MI:0914”(association)	0.350
NPAS1	CIBAR1	psi-mi:“MI:0914”(association)	0.350
DKKL1	VWA8	psi-mi:“MI:0914”(association)	0.350
AFG2B	RCCD1	psi-mi:“MI:0914”(association)	0.350

BioGRID (59): FAM161A (Two-hybrid), DHX32 (Affinity Capture-MS), DHX32 (Affinity Capture-MS), DHX32 (Affinity Capture-MS), DHX32 (Affinity Capture-MS), NUDCD1 (Affinity Capture-MS), MRPL16 (Affinity Capture-MS), DHX32 (Affinity Capture-MS), POLRMT (Affinity Capture-MS), DHX32 (Affinity Capture-RNA), FAM161A (Two-hybrid), DHX32 (Affinity Capture-MS), DHX32 (Affinity Capture-RNA), DHX32 (Affinity Capture-MS), DHX32 (Affinity Capture-MS)

ESM2 similar proteins: A0A0U1RQE8, F1S5L4, O43010, O77512, P06592, P13233, P14714, P42498, P49895, P55004, P97564, Q07071, Q09305, Q0P464, Q0P4Y1, Q1LYL8, Q2KHV5, Q2KIR7, Q3UW68, Q5BK10, Q5FW57, Q5GJ77, Q5PQT3, Q5RFP0, Q60462, Q61586, Q62240, Q64112, Q6IB77, Q6MZZ7, Q6P5U7, Q6QN13, Q6QR59, Q6V915, Q7L7V1, Q804E1, Q8CBA2, Q8T773, Q8WU03, Q91754

Diamond homologs: A1Z9L3, A2A4P0, B4GEU5, B4JT42, B4K5R2, B4RC48, D4A2Z8, F4HYJ7, F4IE66, F4IJV4, F4ILR7, F4IM84, F4JMJ3, F4JRJ6, F4K2E9, F4KGU4, O17438, O22243, O22899, O35286, O42643, O42945, O43143, O45244, O46072, O51767, O60114, O60231, O70133, O94536, P0C7L7, P0CE10, P15938, P20095, P24384, P34305, P34498, P36009, P37024, P43329

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

257 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	156
Likely benign	77
Benign	11

Top pathogenic / likely-pathogenic (0)

SpliceAI

1614 predictions. Top by Δscore:

Variant	Effect	Δscore
10:125838201:CTT:C	donor_loss	1.0000
10:125838202:TTA:T	donor_loss	1.0000
10:125838203:TAC:T	donor_loss	1.0000
10:125838204:A:AC	donor_gain	1.0000
10:125838204:AC:A	donor_loss	1.0000
10:125838205:C:CG	donor_gain	1.0000
10:125838205:CA:C	donor_gain	1.0000
10:125838205:CAG:C	donor_gain	1.0000
10:125838205:CAGT:C	donor_gain	1.0000
10:125838205:CAGTT:C	donor_gain	1.0000
10:125838383:GCAAT:G	acceptor_gain	1.0000
10:125838384:CAAT:C	acceptor_gain	1.0000
10:125838384:CAATC:C	acceptor_gain	1.0000
10:125838385:AAT:A	acceptor_gain	1.0000
10:125838386:AT:A	acceptor_gain	1.0000
10:125838387:TCTGA:T	acceptor_loss	1.0000
10:125838388:C:CC	acceptor_gain	1.0000
10:125838396:CAGAA:C	acceptor_gain	1.0000
10:125838397:A:T	acceptor_gain	1.0000
10:125838400:A:AC	acceptor_gain	1.0000
10:125838400:A:C	acceptor_gain	1.0000
10:125838401:T:C	acceptor_gain	1.0000
10:125838401:T:TC	acceptor_gain	1.0000
10:125838402:T:C	acceptor_gain	1.0000
10:125838402:T:TC	acceptor_gain	1.0000
10:125838403:T:C	acceptor_gain	1.0000
10:125838403:T:TC	acceptor_gain	1.0000
10:125838995:TCTCA:T	donor_loss	1.0000
10:125838996:CTCA:C	donor_loss	1.0000
10:125838997:TCA:T	donor_loss	1.0000

AlphaMissense

4916 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:125867041:A:T	V142D	0.998
10:125867075:C:G	A131P	0.998
10:125867174:A:G	W98R	0.998
10:125867174:A:T	W98R	0.998
10:125866993:A:G	L158P	0.997
10:125867063:C:G	D135H	0.997
10:125867169:A:C	C99W	0.997
10:125867171:A:G	C99R	0.997
10:125867059:A:T	V136D	0.996
10:125880671:A:C	Y52D	0.996
10:125867038:C:T	G143D	0.995
10:125867074:G:T	A131E	0.995
10:125880601:A:G	L75P	0.995
10:125880702:G:C	N41K	0.995
10:125880702:G:T	N41K	0.995
10:125839014:C:T	G623D	0.994
10:125867086:G:T	A127D	0.994
10:125838279:A:G	W664R	0.993
10:125838279:A:T	W664R	0.993
10:125838383:G:T	A629D	0.993
10:125841853:C:T	G478E	0.993
10:125841854:C:G	G478R	0.993
10:125841854:C:T	G478R	0.993
10:125867167:G:T	A100D	0.993
10:125867172:C:A	W98C	0.993
10:125867172:C:G	W98C	0.993
10:125841886:G:T	A467E	0.992
10:125841892:A:G	L465P	0.992
10:125867039:C:G	G143R	0.992
10:125867182:A:T	V95D	0.992

dbSNP variants (sampled 300 via entrez): RS1000006982 (10:125884989 T>C), RS1000118253 (10:125897920 G>A), RS1000227523 (10:125882970 A>G), RS1000237999 (10:125897509 C>G), RS1000324600 (10:125856755 G>A,C), RS1000341279 (10:125851359 C>G), RS1000386519 (10:125856982 A>G), RS1000479301 (10:125838787 G>A), RS1000509601 (10:125862049 C>T), RS1000536201 (10:125838068 T>G), RS1000568413 (10:125894584 A>C), RS1000575446 (10:125863687 G>A), RS1000778407 (10:125848735 G>A), RS1000824454 (10:125856638 A>G,T), RS1000824898 (10:125849090 A>G)

Disease associations

OMIM: gene MIM:607960 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Moderate	Autosomal dominant
retinal disorder	Limited	Autosomal recessive
retinitis pigmentosa	Limited	Autosomal recessive

Mondo (4): thyroid tumor (MONDO:0015074), retinal disorder (MONDO:0005283), neurodevelopmental disorder (MONDO:0700092), retinitis pigmentosa (MONDO:0019200)

Orphanet (1): Rare thyroid tumor (Orphanet:100087)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST90002390_500	Mean corpuscular hemoglobin	9.000000e-16
GCST90002392_552	Mean corpuscular volume	1.000000e-13
GCST90002403_233	Red blood cell count	3.000000e-10

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004527	mean corpuscular hemoglobin
EFO:0004305	erythrocyte count

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625
D012164	Retinal Diseases	C11.768
D012174	Retinitis Pigmentosa	C11.270.684; C11.768.585.658.500; C16.320.290.684

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5465324 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Arsenic	affects methylation, decreases expression, increases abundance	2
aristolochic acid I	decreases expression	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, increases methylation, decreases methylation	1
sodium arsenate	increases abundance, decreases expression	1
sodium arsenite	decreases expression	1
manganese chloride	decreases expression, increases abundance	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II)	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Air Pollutants, Occupational	decreases expression	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Manganese	decreases expression, increases abundance	1
Nickel	decreases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Urethane	decreases expression	1
Cyclosporine	increases expression	1
Aflatoxin B1	decreases methylation	1
Copper Sulfate	decreases expression	1
Lactic Acid	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5391274	Binding	Inhibition of N-terminal thioredoxin-tagged human recombinant DHX32 transformed in Escherichia coli BL21(DE3)pLysS cells	Development of small molecule inhibitors targeting RNA helicase DHX33 as anti-cancer agents. — Bioorg Med Chem Lett

Clinical trials (associated diseases)

484 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01955135	PHASE4	COMPLETED	Anesthesia for Retinopathy of Prematurity
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT00717080	PHASE4	COMPLETED	The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction
NCT00001730	PHASE4	COMPLETED	Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.
NCT00385983	PHASE4	UNKNOWN	Total Thyroidectomy With Harmonic Scalpel®
NCT00400465	PHASE4	COMPLETED	Is the Routine Pressure Dressing After Thyroidectomy Necessary?
NCT01308320	PHASE4	COMPLETED	Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia
NCT03469310	PHASE4	COMPLETED	Minimizing Narcotic Analgesics After Endocrine Surgery
NCT03573960	PHASE4	COMPLETED	A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
NCT04574947	PHASE4	COMPLETED	Lidocaine And Neuromonitoring in Thyroid Surgery
NCT07010393	PHASE4	NOT_YET_RECRUITING	Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT00000114	PHASE3	COMPLETED	Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa
NCT00000116	PHASE3	COMPLETED	Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A
NCT00346333	PHASE3	COMPLETED	Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A
NCT01786395	PHASE3	TERMINATED	Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa
NCT04224207	PHASE3	COMPLETED	Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton’s Jelly Derived Mesenchymal Stem Cells
NCT04636853	PHASE3	COMPLETED	CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration
NCT05537220	PHASE3	ACTIVE_NOT_RECRUITING	Oral N-acetylcysteine for Retinitis Pigmentosa
NCT05800301	PHASE3	COMPLETED	Management of Retinitis Pigmentosa Via Combination of Wharton’s Jelly-derived Mesenchymal Stem Cells and Magnovision
NCT05926583	PHASE3	ACTIVE_NOT_RECRUITING	A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
NCT06388200	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT07082855	PHASE3	NOT_YET_RECRUITING	A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa
NCT07290530	PHASE3	NOT_YET_RECRUITING	24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
NCT00115895	PHASE3	UNKNOWN	The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy
NCT00144079	PHASE3	COMPLETED	Multicenter Study Differentiated Thyroid Carcinoma
NCT00196729	PHASE3	COMPLETED	Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration
NCT00984282	PHASE3	COMPLETED	Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
NCT01551914	PHASE3	UNKNOWN	Medico-economic Evaluation Comparing the Use of Ultrasonic Scissors to the Conventional Techniques of Haemostasis in Thyroid Surgery by Cervicotomy
NCT02112370	PHASE3	COMPLETED	Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy
NCT01373476	PHASE2	COMPLETED	Multicentre, Randomized, Controlled Trial of Qideng Mingmu Capsule in The Treatment of Diabetic Retinopathy
NCT01793090	PHASE2	COMPLETED	EPI-743 in Cobalamin C Defect: Effects on Visual and Neurological Impairment
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00100230	PHASE2	COMPLETED	DHA and X-Linked Retinitis Pigmentosa